CT and Angiography Agreement in Patients from the ISCHEMIA Trial

Computed tomographic (CT) angiography showed a high degree of agreement with conventional angiography to detect significant coronary artery disease and rule out left main disease.

tomografía y la angiografía ISCHEMIA

This imaging study was done on a group of patients before their randomization in the ISCHEMIA trial.

Data are soon to be published in JACC Cardiovascular Imaging and add plenty of evidence in favor of non-invasive diagnosis.

The rise of CT scans came about to solve the opposite problem. In this sense, its high negative predictive value prompted its use to rule out coronary artery disease in patients with unconvincing functional studies.

The power of CT vs. angiography in patients with high ischemic burden in functional assessments plus high probability of coronary artery disease had not been tested yet.

A “blinded” CT was performed before randomization to exclude the opposite ends of coronary artery disease—i.e., left main coronary artery and coronary arteries without lesion.

Randomization then defined the initial strategy, either conservative or invasive (the latter guided by angiography and optimum revascularization).


Read also: Post MI Betablockers for Good?


All lesions ≥50% were defined as anatomically significant.

Lesion in at least one vessel and lack of left main coronary artery lesions were detected by CT in about 1728 patients.

Conventional angiography confirmed the lack of left main coronary artery lesions in 97.1% of cases, and lesions in at least one vessel in 92.2% of cases. Only in 4.9% of patients did angiography not show significant lesions.


Read also: TAVR vs. the Least Invasive Surgically Implanted Valve.


Using a 70%—instead of 50%—stenosis diameter modified this excellent diagnostic precision.

Conclusion

CT showed an excellent agreement with angiography to identify patients with significant coronary artery lesions and rule out left main disease.

j-jcmg-2020-11-012free

Original Title: Coronary CT Angiography Followed by Invasive Angiography in Patients With Moderate or Severe Ischemia-Insights From the ISCHEMIA Trial.

Reference: G.B. John Mancini et al. J Am Coll Cardiol Img 2021, article in press. https://doi.org/10.1016/j.jcmg.2020.11.012.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...